ArticleCurrent medical imaging2025
Discriminating Central Lung Cancer Tumors from Atelectasis using Radiomics Analysis on Contrast-free CT
Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate determination of tumor boundaries is crucial for staging and treating central lung cancer (CLC).
objectiveThis retrospective study aimed to evaluate the feasibility of contrast-free CT radiomics in discriminating CLC tumors from atelectasis.
methodsA total of 58 patients with CLC and associated lung atelectasis, corresponding to 58 tumors and 58 atelectasis regions, were included. Radiomics features were extracted from tumor and atelectasis areas using contrast-free CT images. The least absolute shrinkage and selection operator (LASSO) identified the most differential radiomics features. A logistic regression model (LR) was established and evaluated using 5-fold crossvalidation. Discrimination performance was assessed using the area under the ROC curve (AUC) and decision curve analysis (DCA). Additionally, the potential of visualizing and distinguishing tumors and atelectasis based on contrast-free CT was explored by comparing pixel-level radiomics features with contrast CT.
resultsA total of 1561 radiomics features were extracted, with 356 showing significant statistical differences between tumor and atelectasis. LASSO identified the 10 most differential radiomics features. The LR model trained with these features achieved an AUC of 0.94 (95% CI: 0.89-0.99), sensitivity of 0.88, and specificity of 0.89 in the training group, and an AUC of 0.81 (95% CI: 0.67-0.95), sensitivity of 0.78, and specificity of 0.65 in the validation group. DCA confirmed the clinical utility, and the radiomics feature square_firstorder_10Percentile showed good performance in distinguishing tumors from atelectasis, with consistency to contrast CT.
conclusionContrast-free CT radiomics can effectively discriminate CLC tumors from atelectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.